Dementia of the Alzheimer’s type with delusions – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dementia of the Alzheimer’s type with delusions – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-oral-fesoterodine-in-adults-with-hallucinations-and-delusions-due-to-alzheimer-s-disease-psychosis/ Fri, 29 May 2026 04:02:49 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-oral-fesoterodine-in-adults-with-hallucinations-and-delusions-due-to-alzheimer-s-disease-psychosis/ The study focuses on adults who experience hallucinations and delusions associated with Alzheimer’s disease psychosis. Participants will receive the investigational medication ML-007C-MA, which is taken by mouth as a tablet.

The purpose of the study is to evaluate the long‑term safety and tolerability of the medication. Over several months, participants will take the drug each day and attend regular clinic visits where doctors will check blood work (laboratory tests that look at how the body is functioning), perform an ECG (a quick test that records the heart’s electrical activity), measure vital signs such as blood pressure and weight, and conduct simple memory and thinking assessments to see how cognition changes.

Throughout the trial, any side effects or new health problems will be recorded, and participants may stop the medication if serious issues arise. The overall goal is to determine whether the drug can be used safely for people living with this condition.

]]> A Study of Fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3. https://clinicaltrials.eu/trial/a-study-of-fesoterodine-and-5-1r5r-3-azabicyclo3/ Thu, 30 Apr 2026 13:08:15 +0000 https://clinicaltrials.eu/trial/a-study-of-fesoterodine-and-5-1r5r-3-azabicyclo3/ This study is looking at a condition called Alzheimer’s Disease Psychosis, which can cause people with Alzheimer’s disease to experience hallucinations (seeing or hearing things that are not there) and delusions (believing things that are not true). The treatment being tested is called ML-007C-MA, which is given as a tablet taken by mouth. Some participants will receive ML-007C-MA while others will receive placebo. The purpose of the study is to find out if ML-007C-MA works better than placebo in reducing hallucinations and delusions in people with Alzheimer’s disease psychosis and to check if the treatment is safe.

During the study, participants will be randomly assigned to receive either ML-007C-MA or placebo for a treatment period of seven weeks. The maximum daily dose of ML-007C-MA that may be given is 210 milligrams. Participants will need to have a care partner who can provide information about their symptoms and help them follow the study requirements. The care partner must be in regular contact with the participant and will need to attend all study visits with them. Participants must have been living in the same home or care facility for at least six weeks before joining the study and are expected to stay there throughout the study period.

Throughout the study, doctors will measure changes in hallucinations and delusions using rating scales that assess the severity of these symptoms. They will compare scores from the beginning of the study to scores after seven weeks of treatment. The study will also look at whether the treatment helps with other symptoms such as agitation and aggression in some participants, and will measure how much distress caregivers experience related to the participant’s hallucinations and delusions. Participants must be between 55 and 90 years old and meet specific criteria related to their Alzheimer’s disease diagnosis and the presence of psychotic symptoms for at least two months. A brain scan using MRI or CT must be available or completed during the screening period.

]]> Study on ITI-1284 for Treating Psychosis in Alzheimer’s Patients https://clinicaltrials.eu/trial/study-on-iti-1284-for-treating-psychosis-in-alzheimers-patients/ Wed, 29 Apr 2026 15:04:55 +0000 https://clinicaltrials.eu/trial/study-on-iti-1284-for-treating-psychosis-in-alzheimers-patients/ This clinical trial is focused on studying the treatment of psychosis associated with Alzheimer’s disease. The treatment being tested is a medication called ITI-1284, which is administered in tablet form. The study aims to evaluate how effective and safe this medication is for patients experiencing psychosis, which is a condition that can cause people to see or hear things that are not there or hold false beliefs.

The trial involves comparing the effects of ITI-1284 with a placebo, which looks like the real medication but does not contain the active ingredient. Participants in the study will take the medication once daily for a period of six weeks. During this time, researchers will monitor changes in the participants’ symptoms to determine how well the medication works in reducing the symptoms of psychosis.

The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The goal is to provide a clearer understanding of the potential benefits and safety of ITI-1284 for individuals with psychosis related to Alzheimer’s disease.

]]>